Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy

Further Publications

Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy

JAMA Cardiol

Bhaskaran A, Ben Yaou R, Helms AS, Fayssoil A, Richard P, Stojkovic T, Anselme F, Labombarda F, Chikhaoui C, De Sandre-Giovannoli A, Jeru I, Leturcq F, Vigouroux C, Dembele M, Elliott P, Savvatis K, Zeppenfeld K, Bouguerra H, Charron P, Kumar S, Bonne G, Wahbi K, Lakdawala NK

doi: 10.1001/jamacardio.2025.2069

Further Publications

Prevalence and Clinical Implications of Sleep Apnea in Hypertrophic Cardiomyopathy

JAMA Cardiol

Karim S, Chahal A, Venkataraman S, Deshmukh AJ, Siontis KC, Mansukhani M, Konecny T, Khanji MY, Petersen SE, Gersh BJ, Geske JB, Somers VK

doi: 10.1001/jamacardio.2025.2877

ESC 2025

Cardiovascular Risk and Diseases

Mavacamten monotherapy demonstrates sustained clinical benefits in obstructive hypertrophic cardiomyopathy

Cardiovascular Risk and Diseases

Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases

Eur J Heart Fail

Rossi VA, Sikking MA, Folgheraiter A, Loco CP, Dominguez F, Nihant BSC, Stroeks SLVM, Henkens MTHM, Mora-Ayestarán N, Ramos-López N, Sinagra G, Garcia-Pavia P, Ruschitzka F, Merlo M, Verdonschot JAJ, Heymans SRB

doi: 10.1093/ejhf/xuaf030

Cardiac Arrest or Death

Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy

Circ Arrhythm Electrophysiol

Abdelfattah OM, Sayed A, Al-Jwaid A, Hassan A, Abu Jazar D, Narayanan A, Link MS, Martinez MW

doi: 10.1161/CIRCEP.124.013479

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Heart, Artery and Coronary Diseases

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis

Mayo Clin Proc

Nagaraja V, Lewis BR, Korsapati H, Mene-Afejuku TO, Dillon JJ, Cheungpasitporn W, Gharacholou M, Reeder G, Hibbert B, Best P, Prasad A, Singh M

doi: 10.1016/j.mayocp.2025.11.016

Related content